P8A:SGX
Cordlife Group Ltd
0,12 SGD
0,00%
(0,00) 1D
12. 10., 9:49:20 GMT+8 · SGD
search
Všechny symboly
| Symbol | Cena | Změna | Změna (%) |
|---|
insights_autoGenerování hlavních statistik pro P8A…
Trž. kap.
32,37 mil.
Prům. obj.
1,32 tis.
Objem
0,00
52týd. max.
0,26 SGD
52týd. min.
0,10 SGD
EPS
-0,04 SGD
Akcie v oběhu
267,53 mil.
Počet zaměstnanců
111
Trž. kap.
32,37 mil.
Prům. obj.
1,32 tis.
Objem
0,00
52týd. max.
0,26 SGD
52týd. min.
0,10 SGD
EPS
-0,04 SGD
Akcie v oběhu
267,53 mil.
Počet zaměstnanců
111
Zpravodajské články
Z webových zdrojů a od partnerů z oblasti zpravodajství
MarketBeat
·
před 30 minutami
Plug Power (NASDAQ:PLUG) Hits New 1-Year Low Following Analyst Downgrade
Yahoo Finance
·
před 2 hodinami
SKHY Tracks Worst Month Since Nasdaq Debut: SK Hynix Reportedly Wants To Ship More Chip Tools To China Before Building In US
www.marketscreener.com
·
před 1 hodinou
IPAS Indexo : INDEXO submits draft Company Description to Nasdaq Stockholm for preliminary review
Investor's Business Daily
·
před 3 hodinami
Tech Futures Fall; Anthropic Revenue Jumps, But Not Enough?
Profil
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn.
In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
Informace o Cordlife Group Ltd